MOTS-C Peptide Emerges as Potential Obesity Treatment Amid FDA Review
The MOTS-C peptide is gaining attention as a potential treatment for obesity, distinct from the popular GLP-1 peptides. Although not yet approved for human use, MOTS-C is noted for its energy-boosting effects and is being explored for its ability to mimic exercise's biological effects. It activates AMPK, a key enzyme in energy regulation, which may enhance glucose uptake and fat metabolism. Current research includes a 12-week clinical trial to assess its effectiveness in adults with obesity and prediabetes. The FDA is reviewing MOTS-C among other peptides for potential inclusion in the 503A Bulks List, which would allow its use in compounded medications. 
